Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
LY01019
- Development stage
- Phase 1
- Lead developer
- Boan Biotech
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Administration
- Intravenous
01
Overview
LY01019 is a recombinant humanized monoclonal antibody targeting Claudin 18.2 (CLDN18.2), developed by Shandong Boan Biotechnology, a subsidiary of Luye Pharma. CLDN18.2 is a tight junction protein that is highly expressed in various solid tumors, including gastric, gastroesophageal junction, and pancreatic cancers, while its expression in normal tissues is strictly limited to the gastric mucosa. LY01019 exerts its anti-tumor effects by binding specifically to CLDN18.2 on the surface of tumor cells, thereby inducing antibody-dependent cellular cytotoxicity (ADCC) and complement-dependent cytotoxicity (CDC). The drug is currently being evaluated in Phase 1 clinical trials for the treatment of advanced solid tumors, aiming to provide a targeted therapeutic option for patients with CLDN18.2-positive malignancies.
- Other names
- recombinant humanized anti-CLDN18.2 monoclonal antibody
02
Targets
Claudin 18.2
Beyond the preview
Go deeper on LY01019.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on LY01019.